United Therapeutics/$UTHR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About United Therapeutics

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Ticker

$UTHR
Sector
Primary listing

Employees

1,305

UTHR Metrics

BasicAdvanced
$21B
17.82
$25.63
0.66
-

What the Analysts think about UTHR

Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.

Bulls say / Bears say

United Therapeutics posted record Q2 2025 revenue of $799 million, up 12% year-over-year and marking its twelfth straight quarter of double-digit growth, demonstrating the strength of its main commercial portfolio (BioSpace).
The Board approved a $1 billion stock buyback program running through March 31, 2026, underscoring management's confidence in the company’s balance sheet and future ability to generate cash (BioSpace).
Enrollment wrapped for the Phase 3 ADVANCE OUTCOMES study of oral ralinepag and the Phase 3 TETON 2 trial of nebulized Tyvaso, with results expected in September 2025 and the first half of 2026, offering near-term clinical catalysts (BioSpace).
Q2 2025 EPS was $6.41, missing the Zacks Consensus Estimate of $6.80. Shares fell 5.3% on July 30, indicating investors were dissatisfied with execution (NASDAQ).
Remodulin sales dropped 9% year-over-year to $134.7 million, showing the effects of more generic competition and a patient shift toward easier administration methods (NASDAQ).
Selling, general and administrative expenses rose 20% to $212.5 million year-over-year due to higher personnel and legal costs, putting pressure on operating margins (NASDAQ).
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.

UTHR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

UTHR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $UTHR

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs